CME Group Insider Signals Confidence with Strategic Share Acquisition
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CME Group director Martin J. Gepsman reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Gepsman now beneficially owns a total of 25,299 shares directly. The filing indicates this was a standard director compensation grant rather than an open market purchase.
- Transaction Type: Stock Award (Code A)
- Ownership Form: Direct
- Filing Status: Individual filing
- Role: Director (non-employee)
This insider transaction represents routine director compensation and aligns with standard corporate governance practices for board member equity compensation.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
GEPSMAN MARTIN J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock Class A | 532 | $273.03 | $145K |
Holdings After Transaction:
Common Stock Class A — 25,299 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What is Martin Gepsman's total CME stock ownership after the June 2025 transaction?
Following the reported transaction, Martin J. Gepsman beneficially owned 25,299 shares of CME Group Class A Common Stock directly (Form D).
Who signed the Form 4 filing for CME Director Martin Gepsman?
The Form 4 was signed by Jenelle Chalmers on behalf of Martin J. Gepsman on June 26, 2025.
What is Martin Gepsman's role at CME Group according to the Form 4?
According to the Form 4 filing, Martin J. Gepsman serves as a Director of CME Group Inc., as indicated by the 'X' marked in the Director box under Section 5 (Relationship of Reporting Person to Issuer).